|
[1] ZHANG B,YANG WY. Outlook for the epidemiology and prevention of diabetes in China[J]. Chin J Diabetes,2019,11(1):7-10.(in Chinese)张波，杨文英．中国糖尿病流行病学及预防展望[J]．中华糖尿病杂志，2019,11(1):7-10.
|
|
[2] American Diabetes Association. Erratum. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016; 39(Suppl. 1):s13-s22[J]. Diabetes Care,2016,39(9):1653.
|
|
[3] ZOU X,ZHOU X,ZHU Z,et al. Novel subgroups of patients with adult-onset diabetes in Chinese and US populations[J].Lancet Diabetes Endocrinol,2019,7(1):9-11.
|
|
[4] CHENG YD,YANG DH,XU BY,et al. Characterization and analysis of causes for abnormal liver functions in patients with type 2 diabetes menitus[J]. J Med Res,2017,46(10):76-80,83.(in Chinese)程艳冬，杨东辉，许碧云，等．2型糖尿病患者肝功能损害特征以及原因分析[J]．医学研究杂志，2017,46(10):76-80,83.
|
|
[5] SHIBABAW T,DESSIE G,MOLLA MD,et al. Assessment of liver marker enzymes and its association with type 2 diabetes mellitus in Northwest Ethiopia[J]. BMC Res Notes,2019,12(1):707.
|
|
[6] LEE DH,HA MH,KIM JH,et al. Gamma-glutamyltransferase and diabetes-a 4 year follow-up study[J]. Diabetologia,2003,46(3):359-364.
|
|
[7] HICKMAN IJ,RUSSELL AJ,PRINS JB,et al. Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease?[J]. Diabetes Res Clin Pract,2008,80(1):e10-e12.
|
|
[8] NAUNYN B. Glykosurie und diabetes durch experimentelle Insulte und Krankheiten der Leber[M]//Naunyn B. Der Diabetes mellitus. Vienna,Austria:A. Holder,1898:38-49.
|
|
[9] SHERIGAR JM,CASTRO J,YIN YM,et al. Glycogenic hepatopathy:A narrative review[J]. World J Hepatol,2018,10(2):172-185.
|
|
[10] DHARMALINGAM M,YAMASANDHI PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus[J]. Indian J Endocrinol Metab,2018,22(3):421-428.
|
|
[11] HARRISON SA,BRUNT EM,GOODMAN ZD,et al. Diabetic hepatosclerosis:Diabetic microangiopathy of the liver[J].Arch Pathol Lab Med,2006,130(1):27-32.
|
|
[12] CAI XZ,LI HN,ZHANG W,et al. Clinical characteristics of patients with diabetic hepatopathy[J]. J Pract Diabetol,2014,10(1):42-43.(in Chinese)蔡祥增，李红宁，章雯，等．糖尿病性肝病的临床特点分析[J]．实用糖尿病杂志，2014,10(1):42-43.
|
|
[13] BORA K,BORAH M,CHUTIA H,et al. Presence of concurrent derangements of liver function tests in type 2 diabetes and their relationship with glycemic status:A retrospective observational study from meghalaya[J]. J Lab Physicians,2016,8(1):30-35.
|
|
[14] LU MY,LI J. Pathogenesis and diagnosis and treatment of hepatogenous diabetes[J]. J Jinzhou Med Univ,2018,39(6):92-96.(in Chinese)鲁明月，李静．肝源性糖尿病的发病机制及诊疗进展[J]．锦州医科大学学报，2018,39(6):92-96.
|
|
[15] KURIYAMA S,MIWA Y,FUKUSHIMA H,et al. Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease[J]. J Clin Biochem Nutr,2007,40(2):116-122.
|
|
[16] de SILVA N,BORGES MC,HINGORANI AD,et al. Liver function and risk of type 2 diabetes:Bidirectional mendelian randomization study[J]. Diabetes,2019,68(8):1681-1691.
|
|
[17] HAMED AE,ELSAHAR M,ELWAN NM,et al. Managing diabetes and liver disease association[J]. Arab J Gastroenterol,2018,19(4):166-179.
|
|
[18] XU YQ,JI Y. Liver disease and diabetes mellitus[J]. Chin J Pract Intern Med,2011,31(9):674-675.(in Chinese)徐有青，冀杨．糖尿病与肝病[J]．中国实用内科杂志，2011,31(9):674-675.
|
|
[19] YANG RX,FAN JG. Epidemiological features of non-alcoholic fatty liver diseases[J]. Infect Dis Info,2018,31(2):101-104,111.(in Chinese)杨蕊旭，范建高．非酒精性脂肪性肝病的流行特征[J]．传染病信息，2018,31(2):101-104,111.
|
|
[20] ANSTEE QM,MCPHERSON S,DAY CP. How big a problem is non-alcoholic fatty liver disease?[J]. BMJ,2011,343:d3897.
|
|
[21] MCPHERSON S,HARDY T,HENDERSON E,et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies:Implications for prognosis and clinical management[J]. J Hepatol,2015,62(5):1148-1155.
|
|
[22] RAFIQ N,BAI C,FANG Y,et al. Long-term follow-up of patients with nonalcoholic fatty liver[J]. Clin Gastroenterol Hepatol,2009,7(2):234-238.
|
|
[23] BALLESTRI S,ZONA S,TARGHER G,et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis[J]. J Gastroenterol Hepatol,2016,31(5):936-944.
|
|
[24] TARGHER G,LONARDO A,BYRNE CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus[J]. Nat Rev Endocrinol,2018,14(2):99-114.
|
|
[25] LIU XZ,XU JX. Research progress on the relationship between intestinal flora and nonalcoholic fatty liver[J]. Chin J Gerontol,2019,39(11):2815-2818.(in Chinese)刘晓贞，徐积兄．肠道菌群与非酒精性脂肪肝关系的研究进展[J]．中国老年学杂志，2019,39(11):2815-2818.
|
|
[26] VALENTI L,BUGIANESI E,PAJVANI U,et al. Nonalcoholic fatty liver disease:Cause or consequence of type 2 diabetes?[J]. Liver Int,2016,36(11):1563-1579.
|
|
[27] ABBOUD W,ABDULLA S,AL ZAABI M,et al. Young man with hepatomegaly:A case of glycogenic hepatopathy[J].Case Reports Hepatol,2018,2018:6037530.
|
|
[28] DEEMER KS,ALVAREZ GF. A rare case of persistent lactic acidosis in the ICU:Glycogenic hepatopathy and mauriac syndrome[J]. Case Rep Crit Care,2016,2016:6072909.
|
|
[29] KHOURY J,ZOHAR Y,SHEHADEH N,et al. Glycogenic hepatopathy[J]. Hepatobiliary Pancreat Dis Int,2018,17(2):113-118.
|
|
[30] KING RJ,HARRISON L,GILBEY SG,et al. Diabetic hepatosclerosis:Another diabetes microvascular complication?[J].Diabet Med,2016,33(2):e5-e7.
|
|
[31] CHEN G,BRUNT EM. Diabetic hepatosclerosis:A 10-year autopsy series[J]. Liver Int,2009,29(7):1044-1050.
|
|
[32] WANG Z,HE QH,YANG L,et al. Clinicopathologic features of hepatic diabetic microangiopathy[J]. Chin J Pathol,2012,41(10):676-680.(in Chinese)王征，何清华，杨丽，等．糖尿病肝微血管病变临床病理学观察[J]．中华病理学杂志，2012,41(10):676-680.
|
|
[33] NAZZARI E,GRILLO F,CELIENTO T,et al. Diabetic hepatosclerosis presenting with severe cholestasis[J]. Diabetes Care,2013,36(12):e206.
|
|
[34] ELKRIEF L,RAUTOU PE,SARIN S,et al. Diabetes mellitus in patients with cirrhosis:Clinical implications and management[J]. Liver Int,2016,36(7):936-948.
|
|
[35] LEE WG,WELLS CI,MCCALL JL,et al. Prevalence of diabetes in liver cirrhosis:A systematic review and meta-analysis[J]. Diabetes Metab Res Rev,2019,35(6):e3157.
|
|
[36] GARCA-COMPEN D,GONZLEZ-GONZLEZ JA,LAVALLE-GONZLEZ FJ,et al. Hepatogenous diabetes:Is it a neglected condition in chronic liver disease?[J]. World J Gastroenterol,2016,22(10):2869-2874.
|
|
[37] KUMAR R. Hepatogenous diabetes:An underestimated problem of liver cirrhosis[J]. Indian J Endocrinol Metab,2018,22(4):552-559.
|
|
[38] KAWAGUCHI T,TANIGUCHI E,ITOU M,et al. Insulin resistance and chronic liver disease[J]. World J Hepatol,2011,3(5):99-107.
|
|
[39] MARUYAMA H,KOBAYASHI K,KIYONO S,et al. Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis[J]. Int J Med Sci,2017,14(3):240-245.
|
|
[40] HAMED AE,ELSAHAR M,ELWAN NM,et al. Managing diabetes and liver disease association[J]. Arab J Gastroenterol,2018,19(4):166-179.
|
|
[41] MILMAN N,PEDERSEN P，STEIG T,et al. Clinically overt hereditary hemochromatosis in Denmark 1948-1985:Epidemiology,factors of significance for long-term survival,and causes of death in 179 patients[J]. Ann Hematol,2001,80(12):737-744.
|
|
[42] TRAUSSNIGG S,KIENBACHER C,HALILBASIC E,et al. Challenges and management of liver cirrhosis:Practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH[J].Dig Dis,2015,33(4):598-607.
|
|
[43] TIAN J,MENG QH,LIANG QY,et al. Research progress on the relationship between metabolic diseases and therapeutic drugs and liver cancer[J]. Chin J Clin Pharmacol Ther,2019,24(1):103-110.(in Chinese)田婧，蒙秋华，梁秋云，等．代谢性疾病及治疗药物与肝癌的相关性研究进展[J]．中国临床药理学与治疗学，2019,24(1):103-110.
|
|
[44] SHI F,LEI YP. Effect of statins on hepatocellular carcinoma in patients with type 2 diabetes[J]. J Clin Hepatol,2019,35(1):161-163.(in Chinese)施凤，雷宇鹏．他汀类药物对2型糖尿病患者发生肝细胞癌风险的影响[J]．临床肝胆病杂志，2019,35(1):161-163.
|
DownLoad: